What Just Happened with Day One Biopharmaceuticals and Servier
Servier is acquiring Day One Biopharmaceuticals for $2.5 billion, offering a 68% premium to shareholders. This acquisition highlights the increasing strategic value of rare oncology assets, especially those with approved therapies like Day One's Ojemda for pediatric low-grade glioma. The deal underscores potential for M&A in biotech, rewarding companies with commercial-stage assets addressing unmet medical needs.
Why Did Servier Pay a 68% Premium for Day One Biopharmaceuticals
Servier is acquiring Day One Biopharmaceuticals for $2.5 billion, representing a 68% premium, primarily due to Day One's approved pediatric oncology drug, Ojemda. This acquisition aligns with Servier's strategy to expand its oncology segment and secure innovative assets in high-unmet-need therapeutic areas, especially as large pharmaceutical companies face upcoming patent expirations. The deal provides a significant cash exit for Day One shareholders and signals a robust M&A environment in biotech, driven by the demand for commercially validated assets, lower interest rates, and a focus on therapeutic areas like oncology.
Day One Biopharmaceuticals stock (US23933J1034): Servier’s $2.5 billion takeover puts pediatric cancer focus in the spotlight
Servier is set to acquire Day One Biopharmaceuticals in an all-cash deal valued at $2.5 billion, or $21.50 per share, representing a 68% premium. The acquisition is primarily driven by Day One's pediatric brain cancer drug, Ojemda (tovorafenib), which targets pediatric low-grade glioma and has received FDA and EMA approvals. This deal highlights the strategic value of specialized oncology firms with de-risked lead assets, providing immediate value for Day One shareholders and enhancing Servier’s pipeline in niche markets.
What Does Servier's $2.5 Billion Acquisition Mean for Day One Biopharmaceuticals
Servier is acquiring Day One Biopharmaceuticals for $2.5 billion, offering $21.50 per share, a 68% premium. This acquisition is primarily driven by Day One's FDA-approved drug, Ojemda (tovorafenib), for pediatric low-grade glioma, and aims to expand Servier's rare oncology portfolio. The deal provides a significant and immediate return for Day One shareholders and highlights the value of differentiated therapies in niche oncology markets.
Vestal Point & Ryan Wilder file 13G/A for Day One Biopharma (NASDAQ: DAWN)
Vestal Point Capital, LP and Ryan Wilder filed an amended Schedule 13G/A for Day One Biopharmaceuticals (NASDAQ: DAWN), reporting 0% beneficial ownership as of March 31, 2026. The filing identifies Vestal Point as an investment manager and Mr. Wilder as its Chief Investment Officer and Managing Partner, noting that the amendment is procedural and indicates no material change in ownership. The document explicitly states that the filing should not be construed as an admission of beneficial ownership for Section 13 purposes.
TradingKey
This page provides an overview of Day One Biopharmaceuticals Inc. (DAWN) on TradingKey. It displays the current stock price, market capitalization, and links to financial data, discussions, and analysis for the company. The platform also offers various market tools and educational resources.
Day One and Servier Complete Enrollment in Pivotal Phase 3 FIREFLY-2 Trial of Tovorafenib as a Front-Line Treatment for Pediatric Low-Grade Glioma (pLGG)
Day One Biopharmaceuticals and Servier Group have completed enrollment in their pivotal Phase 3 FIREFLY-2 trial. This trial evaluates tovorafenib (OJEMDA) as a front-line treatment for pediatric low-grade glioma (pLGG) in patients aged 6 months to 25 years. The aim is to extend OJEMDA's indication beyond the relapsed/refractory setting and establish it as a new standard of care, with topline data expected by mid-2027.
[15-12G] Day One Biopharmaceuticals, Inc. SEC Filing
Day One Biopharmaceuticals, Inc. has filed a Form 15-12G with the SEC, certifying the termination of its registration under Section 12(g) and the suspension of its duty to file reports under Sections 13 and 15(d) of the Securities Exchange Act of 1934. The filing, dated May 4, 2026, indicates that the company has only one holder of record. This action follows Servier's recent acquisition of Day One Biopharmaceuticals.
Day One Biopharmaceuticals (DAWN) Moves 7.0% Higher: Will This Strength Last?
Day One Biopharmaceuticals (DAWN) experienced a 7.0% increase in its stock price, outperforming the S&P 500. This rally follows positive analyst revisions for its earnings estimates, suggesting potential continued strength. Investors are advised to monitor whether these upward trends are sustainable despite broader market volatility.
Day One Biopharmaceuticals (DAWN) Projected to Post Earnings on Tuesday
Day One Biopharmaceuticals (NASDAQ:DAWN) is expected to release its Q1 2026 earnings after market close on Tuesday, May 5th. Analysts anticipate an EPS of ($0.31) and revenue of $54.35 million. Despite missing EPS estimates in the prior quarter, the company exceeded revenue expectations, and its stock has shown significant performance with a 50-day moving average of $18.83.
Major holder exits Day One Biopharmaceuticals (DAWN) in $21.50 cash tender
Major shareholder AI Day1 LLC, part of Access Industries and including Len Blavatnik, has fully exited its stake in Day One Biopharmaceuticals (DAWN). The group tendered all common shares into Servier Detroit Inc.'s cash offer at $21.50 per share, and pre-funded warrants were converted at $21.4999 per warrant. As of April 23, 2026, the reporting persons no longer hold any beneficial ownership in DAWN.
Day One Biopharmaceuticals, Inc.(NasdaqGS: DAWN) dropped from Russell 2500 Index
Day One Biopharmaceuticals, Inc. (NasdaqGS: DAWN) has been dropped from the Russell 2500 Index, as well as multiple other Russell indices including the Russell 2000 Index and Russell 3000 Index. The biopharmaceutical company focuses on developing targeted therapies for life-threatening diseases, with lead product candidates such as tovorafenib and pimasertib. This removal from several prominent indices signals a potential re-evaluation of its market position.
Day One Biopharmaceuticals (NASDAQ:DAWN) Rating Increased to Hold at Wall Street Zen
Wall Street Zen upgraded Day One Biopharmaceuticals (NASDAQ:DAWN) to a "Hold" rating. The company has a consensus "Hold" rating with an average target price of $23.29 from analysts. Despite the stock opening at its 12-month high, it reported a quarterly EPS miss, negative net margin, and negative ROE, with analysts forecasting a negative EPS for the current year.
Servier deal cancels Day One (NASDAQ: DAWN) COO’s stock and options
Day One Biopharmaceuticals' COO and CFO, Charles N. York II, had all his equity, including common stock, stock options, and restricted stock units, canceled due to the company's merger with Servier. Each share of Day One common stock was cashed out at $21.50 per share on April 23, 2026. Prior to cancellation, all unvested options and RSUs fully vested and were converted into cash based on the merger consideration.
Servier buyout: Day One (NASDAQ: DAWN) CEO equity cashed out
Day One Biopharmaceuticals, Inc.'s CEO, Jeremy Bender, and related entities have disposed of all their equity in connection with the company's cash merger with Servier. Each outstanding share of Day One common stock was converted into the right to receive $21.50 per share in cash on April 23, 2026. This transaction included the cancellation and cash conversion of Bender's directly held common stock, RSUs, and stock options, resulting in zero remaining shares and derivative awards for the reported positions.
Day One Biopharma (DAWN) director’s options and RSUs cashed out at $21.50
Day One Biopharmaceuticals director Garland J. Scott cashed out restricted stock units and stock options following the company's merger with Servier. On April 23, 2026, Scott disposed of 15,000 restricted stock units and various stock option grants totaling over 169,000 shares. All equity awards were fully vested and converted into cash at $21.50 per share, or $21.50 minus the exercise price for options.
Director at Day One Biopharmaceuticals (DAWN) has equity awards cashed out in merger
Garry A. Nicholson, a director at Day One Biopharmaceuticals (DAWN), reported the disposition of 15,000 restricted stock units and multiple stock option grants in connection with the company's merger with Servier Pharmaceuticals LLC. Upon the merger's closing on April 23, 2026, all outstanding equity awards fully vested, were canceled, and converted into cash at an offer price of $21.50 per share. Nicholson now holds no derivative securities from these awards.
Day One Biopharmaceuticals Ends ATM Equity Distribution Pact With Piper Sandler, JonesTrading Amid Merger
Day One Biopharmaceuticals has terminated its Equity Distribution Agreement for at-the-market offerings with Piper Sandler and JonesTrading, effective April 20, 2026. This decision was made in connection with the closing of its merger, which will lead to the company's delisting and cessation of SEC reporting. No termination fees were incurred.
Servier completes the acquisition of Day One Biopharmaceuticals
Servier has completed its acquisition of Day One Biopharmaceuticals for approximately $2.5 billion, enhancing its oncology portfolio, particularly in rare cancers. This acquisition includes Day One's FDA-approved drug, OJEMDA™ (tovorafenib), for pediatric low-grade glioma, and a robust pipeline in clinical-stage rare cancer treatments. The move aligns with Servier's 2030 ambition to strengthen its position in rare cancers and integrate innovative scientific capabilities.
Day One Biopharmaceuticals (DAWN) delisted from Nasdaq; Exchange cites compliance
Day One Biopharmaceuticals (DAWN) has been delisted from the Nasdaq Stock Market, as announced via a Form 25 SEC filing. Both Nasdaq and the issuer acknowledge compliance with the relevant rules for voluntary withdrawal and delisting. The delisting means DAWN's common stock will no longer trade on Nasdaq, with future trading venues and implications for shareholders to be detailed in subsequent notices.
Day One Biopharmaceuticals' David K. Lee and Danielle Button become officers and directors after merger
Following a merger, Day One Biopharmaceuticals announced that David K. Lee and Danielle Button have been appointed as officers and directors of the surviving corporation. Simultaneously, eight previous directors, including Jeremy Bender and Habib Dable, ceased their service. These changes are per the terms of the merger agreement and became effective at the Effective Time.
Day One Biopharmaceuticals Received Notice of Delisting
Day One Biopharmaceuticals (DAWN) confirmed the completion of its merger on April 23, 2026, and has requested Nasdaq to issue a trading halt and file for delisting and deregistration of its shares. The company also plans to file a Form 15 to terminate SEC reporting obligations. Trading was halted starting the evening of April 22, 2026.
DAWN: Day One Pharmaceuticals removes S-3 registrations after merger with Servier
Day One Pharmaceuticals, Inc. has filed post-effective amendments to withdraw and deregister all unsold securities under its Form S-3 registration statements (No. 333-274521 and No. 333-281822) following its merger with Servier. The company became a wholly owned subsidiary of Servier on April 23, 2026, as per a merger agreement dated March 6, 2026, leading to the termination of all related offerings. This administrative deregistration precludes future capital-raising via these specific registration statements.
Servier buyout: Day One (NASDAQ: DAWN) counsel’s equity cashed out at $21.50
Day One Biopharmaceuticals' General Counsel & Secretary Adam Dubow disposed of all his equity holdings, including common stock, restricted stock units, and stock options, as part of the company's cash merger with Servier. On April 23, 2026, all shares and equity awards were either purchased or converted into the right to receive $21.50 per share in cash. This transaction resulted in Dubow holding zero shares and zero derivatives in the company post-merger.
(DAWN) Price Dynamics and Execution-Aware Positioning
Day One Biopharmaceuticals Inc. (NASDAQ: DAWN) is currently showing neutral near and mid-term readings, which could moderate its long-term positive bias. The analysis indicates elevated downside risk due to a lack of additional long-term support signals. Three distinct institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—have been generated by AI models, catering to different risk profiles.
150,925 Shares in Day One Biopharmaceuticals, Inc. $DAWN Acquired by Massachusetts Financial Services Co. MA
Massachusetts Financial Services Co. MA has acquired 150,925 shares of Day One Biopharmaceuticals (NASDAQ:DAWN) in the fourth quarter, valued at approximately $1.407 million. This new position represents about 0.15% of the company. Despite institutional buying, corporate insiders have been net sellers in the last three months, and analysts currently hold an average "Hold" rating for DAWN with a target price of $23.29.
[SC TO-T/A] Day One Biopharmaceuticals, Inc. Amended Third-Party Tender Offer | DAWN SEC Filing - Form SC TO-T/A
Servier Detroit Inc. has filed Amendment No. 3 to its Tender Offer Statement on Schedule TO concerning the acquisition of Day One Biopharmaceuticals, Inc. This amendment primarily addresses new litigation, specifically two lawsuits filed in the Supreme Court of the State of New York by purported stockholders. These lawsuits allege negligent misrepresentation and concealment, claiming a failure to disclose material information regarding the tender offer in the Schedule 14D-9.
[SC 14D9/A] Day One Biopharmaceuticals, Inc. Amended Tender Offer Recommendation
Day One Biopharmaceuticals, Inc. has amended its Schedule 14D-9 regarding a tender offer, revising Centerview Partners’ valuation analyses and adding disclosures about related shareholder litigation. The amendment restates selected public-company and precedent-transaction multiples, updates a DCF and management projections, and includes details on two complaints and additional demand letters concerning the proposed merger. The company continues to recommend the $21.50 per-share offer despite the updated valuation ranges and ongoing legal challenges.
Access Industries group tenders Day One (DAWN) 12.9M-share stake at $21.50
AI Day1 LLC, part of the Access Industries group, has tendered its entire 12,929,322-share stake in Day One Biopharmaceuticals (DAWN) at $21.50 per share. This tender was made into Servier Detroit Inc.'s cash buyout offer on April 9, 2026. The stake represented 12.52% of Day One's outstanding common stock.
Day One Biopharmaceuticals stock reaches 52-week high of $21.48
Day One Biopharmaceuticals (DAWN) stock recently hit a 52-week high of $21.48, showcasing a 201.54% impressive 1-year return and a 130% year-to-date gain, with a market capitalization of $2.22 billion. This surge is likely due to biopharmaceutical advancements and strategic initiatives, despite TradingPro suggesting it's currently overvalued. However, the company is being acquired by Servier for $2.5 billion ($21.50 per share), leading to several analyst downgrades to Neutral or Hold ratings.
Are WSR, TERN, RLYB, DAWN Obtaining Fair Deals for their Shareholders?
Halper Sadeh LLC, an investor rights law firm, is investigating Whitestone REIT (WSR), Terns Pharmaceuticals, Inc. (TERN), Rallybio Corporation (RLYB), and Day One Biopharmaceuticals, Inc. (DAWN) for potential violations of federal securities laws and/or breaches of fiduciary duties related to their recent sales or mergers. The firm is concerned that insiders may receive substantial financial benefits not available to ordinary shareholders and that the transactions might limit superior competing offers. Halper Sadeh LLC represents investors and may seek increased consideration, additional disclosures, or other relief on their behalf.
FMR LLC holds 23,639.69 shares in Day One Biopharmaceuticals (NASDAQ: DAWN) amendment
FMR LLC, along with Abigail P. Johnson, has filed an amended Schedule 13G/A report indicating beneficial ownership of 23,639.69 shares of Day One Biopharmaceuticals (NASDAQ: DAWN) common stock. This represents 0.0% of the class. The filing specifies that FMR LLC has sole dispositive power over these shares, and no other person holds more than 5% of DAWN stock.
HSR waiting period ends for Day One Biopharma (NASDAQ: DAWN) — Offer stays subject to conditions
Day One Biopharma announced that the HSR waiting period for its pending cash tender offer by Servier has been terminated early by the FTC on April 7, 2026. This satisfies one key condition of the $21.50 per share offer, which was initially filed on March 26, 2026. While the HSR regulatory hurdle is cleared, the offer remains subject to other specified conditions.
Servier (DAWN) wins FTC early HSR termination, clearing HSR hurdle for tender offer
Servier S.A.S. and its subsidiaries announced that the FTC granted early termination of the HSR waiting period for their tender offer for Day One Biopharmaceuticals, Inc. (DAWN) shares, effective April 7, 2026, at 1:37 p.m. Eastern Time. This satisfies a key regulatory condition, although the tender offer remains subject to other specified conditions. The announcement was made via an amendment to the Schedule TO filing.
Day One Biopharmaceuticals (NASDAQ:DAWN) Sets New 1-Year High - What's Next?
Day One Biopharmaceuticals (NASDAQ:DAWN) recently hit a new 52-week high of $21.47, trading with heavy volume. Despite this, analyst consensus is a "Hold" with an average target price of $23.29, and several firms have reduced their price objectives. The company reported a quarterly EPS miss but a revenue beat, and institutional ownership remains high while insiders have recently sold shares.
JonesTrading Maintains Day One Biopharmaceuticals(DAWN.US) With Hold Rating, Maintains Target Price $21.5
JonesTrading analyst Soumit Roy has reiterated a Hold rating for Day One Biopharmaceuticals (DAWN.US), maintaining a target price of $21.5. According to TipRanks data, Roy's past performance shows a 32.2% success rate and an average return of -7.2% over the last year. This information is intended for informational purposes only and not as an investment recommendation.
SG Americas Securities LLC Buys 323,747 Shares of Day One Biopharmaceuticals, Inc. $DAWN
SG Americas Securities LLC significantly increased its stake in Day One Biopharmaceuticals Inc. (NASDAQ:DAWN) by 1,228.9% in the fourth quarter, now owning 350,092 shares valued at $3.26 million. Despite reaching a 12-month high in share price and beating revenue estimates, the company reported a net loss and continues to have negative margins and returns. Analyst sentiment for DAWN is predominantly "Hold" with a consensus price target of $23.29, alongside recent insider selling.
Hennion & Walsh Asset Management Inc. Buys 218,383 Shares of Day One Biopharmaceuticals, Inc. $DAWN
Hennion & Walsh Asset Management Inc. significantly increased its stake in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) by 229.7% in the fourth quarter, now holding 313,455 shares valued at $2.92 million. This comes as institutional investors collectively own 87.95% of the company, despite recent insider selling totaling 36,461 shares worth $422,948. Day One Biopharmaceuticals reported mixed quarterly results with an EPS miss but a revenue beat, while analysts maintain a consensus "Hold" rating with a target price of $23.29.
Day One Biopharmaceuticals (Nasdaq:DAWN) - Stock Analysis
Day One Biopharmaceuticals (Nasdaq:DAWN) is a commercial-stage biopharmaceutical company with a market cap of US$2.2 billion. The stock is currently trading at US$21.42, which analysts suggest is 0.4% undervalued. Its lead product, OJEMDA (tovorafenib), is positioned for revenue growth with expanding clinical indications and European approvals, though some risks related to single-product dependency and regulatory scrutiny remain.
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Short Interest Down 20.3% in March
Day One Biopharmaceuticals (NASDAQ:DAWN) experienced a 20.3% decrease in short interest in March, with the total falling to 8,091,418 shares. The company has an average "Hold" rating from Wall Street analysts with a target price of $23.29, following several recent downgrades. Insider selling by the CFO and another insider was reported, while institutional ownership remains high at 87.95%.
(DAWN) Risk Channels and Responsive Allocation
The article provides an AI-generated analysis for Day One Biopharmaceuticals Inc. (NASDAQ: DAWN), indicating a near-term neutral sentiment but mid and long-term strength. It details specific institutional trading strategies, including long, breakout, and short positions with entry zones, targets, and stop losses. The analysis also presents multi-timeframe signal strengths, support, and resistance levels for DAWN.
Are SEM, DAWN, VRE Obtaining Fair Deals for their Shareholders?
Halper Sadeh LLC, an investor rights law firm, is investigating Select Medical Holdings Corporation (SEM), Day One Biopharmaceuticals, Inc. (DAWN), and Veris Residential, Inc. (VRE) for potential violations of federal securities laws and breaches of fiduciary duties. The firm is concerned that the proposed sales of these companies may not offer fair deals to ordinary shareholders, as insiders could receive disproportionate financial benefits. Halper Sadeh LLC encourages shareholders to contact them to discuss their rights and options.
Day One Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Day One Biopharmaceuticals, Inc. - DAWN
Kahn Swick & Foti, LLC is investigating the proposed sale of Day One Biopharmaceuticals, Inc. (NasdaqGS: DAWN) to Servier for $21.50 per share in cash. The law firm is seeking to determine if this consideration and the process leading to it are adequate, or if the Company is undervalued. Shareholders who believe the transaction undervalues the company are encouraged to contact KSF.
Day One Biopharmaceuticals Executives Sell Shares Amid Legal Firm's Scrutiny of $21.50 Offer
Executives at Day One Biopharmaceuticals have sold $422,980 worth of shares, raising concerns as a law firm investigates if Servier's $21.50 per share acquisition offer undervalues the company, especially after a 123.5% stock surge. This insider selling contrasts with some institutional accumulation, like BlackRock's increased stake, but aligns with a net withdrawal of institutional ownership and hints at potential undervaluation if the deal closes.
Vanguard amends holdings for Day One Biopharmaceuticals (NASDAQ: DAWN), reports 0 shares
The Vanguard Group filed an amended Schedule 13G/A, reporting 0 shares of Day One Biopharmaceuticals Inc. (NASDAQ: DAWN), representing 0% beneficial ownership. This change is due to an internal realignment on January 12, 2026, causing Vanguard's subsidiaries and business divisions to report their holdings separately, rather than indicating a sale of shares. The filing was signed by Ashley Grim, Head of Global Fund Administration, on March 26, 2026.
Day One Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Day One Biopharmaceuticals, Inc. - DAWN
Kahn Swick & Foti, LLC (KSF) is investigating the proposed sale of Day One Biopharmaceuticals, Inc. (NasdaqGS: DAWN) to Servier for $21.50 per share in cash. The law firm is examining whether this consideration and the process leading to the transaction are adequate and fair to shareholders. Shareholders who believe the Company is undervalued are encouraged to contact KSF for legal consultation regarding their rights.
Servier adds exhibit to Day One Biopharma tender offer (DAWN)
Servier S.A.S., Servier Pharmaceuticals LLC, and Servier Detroit Inc. (the Servier Parties) have filed an Amendment No. 1 to their Schedule TO regarding the tender offer for Day One Biopharmaceuticals (DAWN). This amendment adds an "Integration Presentation" as an exhibit to the existing tender offer statement. The core terms of the tender offer remain unchanged, with the amendment solely supplementing Item 12 (Exhibits).
Servier offers $21.50 per share for Day One (NASDAQ: DAWN) in agreed deal
Servier is offering $21.50 per share in cash to acquire Day One Biopharmaceuticals (NASDAQ: DAWN) in an agreed deal. The Offer, which started on March 26, 2026, and is set to expire on April 22, 2026, has been recommended by Day One's board of directors, who believe it provides significant and certain value to shareholders. Key conditions include a majority of shares tendered, HSR clearance, and no legal restraints, with Day One becoming a wholly-owned subsidiary of Servier upon completion.
Servier (DAWN) offers $21.50 in cash to buy Day One Biopharma shares
Servier Detroit Inc. has launched a cash tender offer to acquire all outstanding common shares of Day One Biopharmaceuticals, Inc. (DAWN) for $21.50 per share. The offer is outlined in an Offer to Purchase document dated March 26, 2026, and is a key part of a previously announced Agreement and Plan of Merger from March 6, 2026. This acquisition aims to expand Servier's portfolio in rare oncology.
GLAZER CAPITAL, LLC Acquires Significant Stake in Day One Biopharma
GLAZER CAPITAL, LLC has acquired 5,615,390 shares of Day One Biopharmaceuticals Inc (NASDAQ: DAWN) at $21.27 per share, representing 3.37% of GLAZER CAPITAL's portfolio and a 5.40% stake in Day One. This strategic investment highlights GLAZER CAPITAL's interest in the biotechnology sector and Day One's potential for growth in targeted cancer therapies, particularly for pediatric patients, despite current profitability challenges. Other notable investors, such as Ken Fisher, also show interest in Day One Biopharmaceuticals Inc.
